-- 週三,歐洲股市普遍下跌,史托克歐洲指數下跌0.4%,富時100指數下跌0.5%,法國CAC40指數下跌0.7%,瑞士市場指數下跌0.3%,德國DAX指數上漲0.2%。 歐盟統計局(Eurostat)的初步數據顯示,經季節性調整後,歐元區和歐盟2月工業生產均成長0.4%。 彭博調查的分析師先前預期為0.3%。 企業新聞方面,葛蘭素史克(GSK)週三宣布,已完成對35Pharma的收購,交易金額達9.5億美元。此次收購將一種用於治療肺動脈高壓的實驗性療法納入其呼吸、免疫和發炎產品線。 此次交易使葛蘭素史克完全擁有HS235的所有權。 HS235是一種處於臨床階段的蛋白質療法,可針對激活素受體訊號通路,該通路是肺動脈高壓的臨床驗證標靶。 葛蘭素史克(GSK)表示,該候選藥物的設計具有更高的選擇性,可望降低目前治療方案相關的出血、心包膜積液和劑量限制性血紅素升高等風險。 這家英國製藥公司的股價在倫敦下跌了2.3%。 根據彭博新聞社週三援引知情人士報道,Stellantis正在考慮重啟與東風汽車的合作,雙方將在歐洲和中國聯合生產汽車。 匿名消息人士告訴彭博社,透過這項合作,東風汽車可以使用Stellantis在歐洲未充分利用的工廠。 Stellantis尚未回覆的置評請求。 這家汽車製造商的股價在巴黎上漲了2.1%。 Aegon週三表示,已同意以20億英鎊(約27.1億美元)的價格將Aegon UK出售給Standard Life。 據該公司稱,該交易所得包括7.5億英鎊現金和Standard Life 15.3%的股份。 Aegon表示計劃在今年底前完成此次出售。 這家金融服務集團的股票在阿姆斯特丹下跌了0.2%。 Equinor旗下的Danske Commodities週三表示,該公司在3月裁減了約28個職位,旨在推動其新的商業策略。 據人力資源與文化副總裁Jonas Skovbjerg Hansen發給的一份聲明稱,作為組織架構調整的一部分,一些職位已被取消,同時也在設立新的職位。 這家挪威煉油商的股票在奧斯陸下跌了2.3%。
Related Articles
Research Alert: CFRA Maintains Hold Rating On Shares Of United Rentals Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price to $1,100 from $950 following a strong first quarter, valuing shares at 20.5x our 2027 EPS outlook of $54.28 (in line with previous estimate; 2026 EPS also in line). We believe a higher multiple is justified given URI's firming market leadership within an expanding rental equipment industry. A robust Q1 beat enabled URI to raise its full-year revenue guidance to $16.9B-$17.4B and adjusted EBITDA to $7.625B-$7.875B, citing momentum heading into a busy season. With leverage well below historical levels, we believe accretive M&A deals could serve as a potential catalyst for additional guidance increases. Margin compression has been a sticky issue for URI, but Q1 indicated that pricing may have turned around and that headwinds are starting to ease as quarterly results begin to lap when tariff-related inflation began to pick-up. We remain cautious on margins, though are encouraged by signs of stabilization. New project activity is likely supporting pricing trends, in our view.
Petro Rabigh Emerges From Loss in Q1; Revenue Grows
Rabigh Refining and Petrochemical (SASE:2380), d/b/a Petro Rabigh, said Sunday it swung back to profit in the first quarter of 2026, while revenue increased year over year.Net profit attributable to shareholders of the issuer for the three months ended March 31 was 1.47 billion Saudi riyals, compared with the attributable loss of 691 million riyals earlier. EPS moved to 0.88 riyal from a loss per share of 0.41 riyal.The Tadawul-listed oil refining and petrochemical company's revenue was 14.85 billion riyals, compared with 11.21 billion riyals a year ago.
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.